Treatment of cancers with a regimen of targeted radionuclide therapy and dual car t cell therapy
AssigneeWisconsin Alumni Research Foundation
InventorsZachary Morris, Christian Capitini, Quaovi Sodji
Life of this patent
Estimating the term…
Abstract
Described herein are genetically modified bispecific immune cells such as bicistronic and bivalent immune cells. The bispecific immune cells include an antigen recognition domain that specifically binds a tumor-specific antigen and an antigen recognition domain that specifically binds a radiation-induced cell surface marker. Also described are methods of treating cancer in a subject including administering to the subject a dose of a targeted radionuclide therapy (TRT) agent, and administering to the subject the genetically modified bispecific immune cell.
Claims23
A genetically modified bispecific immune cell, comprising
- a genetically modified bicistronic immune cell comprising
- a first expressed chimeric antigen receptor (CAR) construct comprising a first extracellular domain linked to a first intracellular domain through a first transmembrane domain, wherein the first extracellular domain comprises an antigen recognition domain that specifically binds a tumor-specific antigen, and
- a second expressed CAR construct comprising a second extracellular domain linked directly or indirectly to a second intracellular domain through a second transmembrane domain, wherein the second extracellular domain comprises an antigen recognition domain that specifically binds a radiation-induced cell surface marker,
- or
- a genetically modified bivalent immune cell comprising a bivalent expressed CAR construct comprising a bivalent extracellular domain which comprises a first antigen recognition domain that specifically binds a tumor-specific antigen and a second antigen recognition domain that specifically binds a radiation-induced cell surface marker, linked to a single intracellular domain through a single transmembrane domain.
Dependencies are inferred from the claim text.